Lipocine is touting positive late-stage results for its testosterone replacement pill, gearing up for intense FDA scrutiny amid a sea change in how the regulator looks at so-called low-T treatments.

…read more

Source: Lipocine’s low-T drug hits the mark in Phase III. Now it has to sway the FDA